Skip to main content
Article thumbnail
Location of Repository

Modeling payback from research into the efficacy of left-ventricular assist devices as destination therapy

By Alan J. Girling, Guy Freeman, Jason P. Gordon, Philip Poole-Wilson, David A. Scott and Richard Lilford


Objectives: Ongoing developments in design have improved the outlook for left-ventricular assist device (LVAD) implantation as a therapy in end-stage heart failure. Nevertheless, early cost-effectiveness assessments, based on first-generation devices, have not been encouraging. Against this background, we set out (i) to examine the survival benefit that LVADs would need to generate before they could be deemed cost-effective; (ii) to provide insight into the likelihood that this benefit will be achieved; and (iii) from the perspective of a healthcare provider, to assess the value of discovering the actual size of this benefit by means of a Bayesian value of information analysis.\ud \ud Methods: Cost-effectiveness assessments are made from the perspective of the healthcare provider, using current UK norms for the value of a quality-adjusted life-year (QALY). The treatment model is grounded in published analyses of the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial of first-generation LVADs, translated into a UK cost setting. The prospects for patient survival with second-generation devices is assessed using Bayesian prior distributions, elicited from a group of leading clinicians in the field.\ud \ud Results: Using established thresholds, cost-effectiveness probabilities under these priors are found to be low (.2 percent) for devices costing as much as £60,000. Sensitivity of the conclusions to both device cost and QALY valuation is examined.\ud \ud Conclusions: In the event that the price of the device in use would reduce to £40,000, the value of the survival information can readily justify investment in further trials

Topics: RA
Publisher: Cambridge University Press
Year: 2007
OAI identifier:

Suggested articles


  1. A pilot study on the use of decision theory and value of information analysis as part of the NHS health technology assessment programme. Health Technol Assess. doi
  2. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). doi
  3. Advanced heart failure: Feasibility study of long-term continuous axial flow pump support. doi
  4. AJ; and the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. doi
  5. (1996). An economic approach to clinical trial design and research priority-setting. Health Econ. doi
  6. (1961). Applied statistical decision theory. doi
  7. (2006). Association. Heart disease and stroke statistics - doi
  8. Axial flow pumps. doi
  9. Bayesian approaches to clinical trials and health-care evaluation. doi
  10. Cardiac replacement: Estimation of need, demand and supply.
  11. (1995). Changes in healthrelated quality of life and depression in heart transplant recipients. J Heart Lung Transplant.
  12. ClaxtonK.Theirrelevanceofinference:Adecision-makingapproach to the stochastic evaluation of health care technologies.
  13. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. doi
  14. (1974). Decision analysis expert use. Manage Sci.
  15. (1983). Diagnosing the experience curve. JM a r k . doi
  16. Does a rotary pump provide full cardiac decompression and circulatory support?— from clinical experiences of HeartMate II with severe congestive heart failure patients. doi
  17. (2004). Donor management and selection for heart transplantation. Semin Thorac Cardiovasc Surg.
  18. (2004). et al; on behalf of UK Transplant Cardiothoracic Advisory Group. Long-term patient survival for heart transplant recipients in the UK.
  19. Expected value of sample information calculations in medical decision modeling. Med Decis Making. doi
  20. (2002). Federal Drug Administration. FDA approves heart assist pump for permanent use. FDA. doi
  21. (2007). from research into LVADs
  22. (1998). Heart failure: A medical hydra. doi
  23. Hospital costs for left ventricular assist devices for destination therapy: Lower costs for implantation in the post-REMATCH era. doi
  24. (2000). Improving the effi-ciency and relevance of health technology assessment: The role of iterative decision analytic modelling. Report No. Discussion Paper 179. York: Centre for Health Economics;
  25. Left ventricular assist devices as permanent heart failure therapy: The price of progress. doi
  26. Left ventricular assist devicesasdestinationtherapy:Anewlookatsurvival.JThorac Cardiovasc Surg.
  27. Long-term destination therapy with the HeartMate XVE left ventricular assist device. Improved outcomes since the REMATCH Study. Congest Heart Fail. doi
  28. (2007). Managing elderly patients with end-stage heart failure.
  29. (2006). Mechanical circulatory support therapy as a bridge to transplant or recovery (new advances). Curr Opin Cardiol. doi
  30. Medical device prices follow the experimental curve. J Med Marketing. doi
  31. National Institute for Clinical Excellence and its value judgments. doi
  32. (2006). Progress of rotary blood pumps. Artif Organs. doi
  33. (1997). Quality of life with an implanted left ventricular assist device. Ann Thorac Surg. doi
  34. (2000). Selecting treatments: A decision theoretic approach. doi
  35. (1998). Sensitivity analysis and the expected value of perfect information. Med Decis Making. doi
  36. (2004). Special Report: Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure. Technol Eval Cent Asses Program Exec Summ.
  37. Statistical methods for eliciting probability distributions. JA mS t a tA s s o c . doi
  38. The application and misapplication of the experience curve. doi
  39. (2005). The clinical and costeffectiveness of left ventricular assist devices for end-stage heart failure: A systematic review and economic evaluation. Health Technol Assess. doi
  40. The DeBakey ventricular assist device. doi
  41. (2003). The green book: Appraisal and evaluation in central government.
  42. (1999). The REMATCH Trial: Rationale, design, and end points. randomized evaluation of mechanical assistance for the treatment of congestive heart failure. Ann Thorac Surg.
  43. The statistical basis of public policy: A paradigm shift is overdue. doi
  44. The value of information and optimal clinical trial design. Stat Med. doi
  45. (2006). Third-generation blood pumps with mechanical noncontact magnetic bearings. Artif Organs. doi
  46. Trends of congestive heart failure epidemiology: Contrast with clinical trial results.
  47. (2005). Ventricular assist devices for durable support. Circulation. doi
  48. (2002). Ventricular assist system: Summary of safety and effectiveness. Food and Drug Administration.
  49. Will left-ventricular assist device therapy replace heart transplantation in the foreseeable future? Curr Opin Cardiol. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.